Microsaic Systems Signs Commercial Agreement
News Apr 11, 2013
Microsaic Systems plc has announced the signing of a second major agreement to provide its miniature mass spectrometer - the Microsaic 4000 MiD® - as an Original Equipment Manufacturer (OEM).
The agreement is for the global, non-exclusive marketing and sale of the 4000 MiD® as a stand-alone instrument for use in specified applications.
The terms of the agreement include commitments to minimum quantities during an initial period of 42 months. Shipments under the agreement are anticipated to commence in Q3 2013.
Colin Jump, Chief Executive of Microsaic Systems, commented: "The compact nature of our mass spectrometer technology makes it uniquely suited to address the needs of the modern laboratory, both as a stand-alone product or integrated with complementary instruments to create entirely new product offerings. This second OEM agreement, which resulted directly from expressions of customer interest, means we now have partnerships for our MiD® system in both areas, following our first agreement announced last year for a combined system. Minimum volume commitments in the agreements provide both areas with a material underpinning of demand. On-going discussions with potential partners and customers convince us there is significant additional demand for our product across multiple application areas and formats, and we look forward to announcing further progress in due course.”
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE
Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule InhibitorsNews
A new original research article presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.READ MORE